Company intelligence / Profile preview

Ad4 Pharma

Ownership: Private
Development stage: Other

Overview

Ad4 Pharma was a private pharmaceutical/biotech company based in the United States. Its only disclosed pipeline asset was BDD-10103, which targeted muscle spasticity and previously back pain. The program has been discontinued and there are no active clinical results or ongoing programs reported as of August 2024.

Therapeutic areas: RheumatologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

BiRDS Pharma GmbH (originator organization for BDD-10103)

Beyond the preview

Go deeper on Ad4 Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad4 Pharma.

Explore the full profile